ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 935

Targeting Glycolysis in Rheumatoid Arthritis

Monica Guma1, Alessia Lodi2, Ajit Divakaruni3, Anne Murphy3, Stefano Tiziani4 and Gary S. Firestein5, 1Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 2nutritional Sciences, University of Texas at Austin, Austin, TX, 3Pharmacology, University of California, San Diego, La Jolla, CA, 4Nutritional Sciences, University of Texas at Austin, Austin, TX, 5Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, Fibroblasts, metabolism and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Rheumatoid Arthritis - Animal Models I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Many of the signaling pathways activated in inflammation have a profound effect on cell metabolism. However, little is known about metabolome in rheumatoid arthritis (RA), particularly in fibroblast-like synoviocytes (FLS). The shift from ATP generation through oxidative phosphorylation to glycolysis has been implicated not only in tumor cells growth but also in immune cell function upon activation. To determine the role of glycolysis in arthritis, we examined glucose metabolism in FLS and evaluated whether this pathway could play a role in inflammation and joint damage.

 

Methods: The glucose profile of FLS cells was determined by 1H-MRS. Analysis of FLS oxygen consumption/extracellular acidification after LPS stimulation used Seahorse technology.  FLS function using the glycolysis inhibitor 2-Deoxy-D-glucose (2-DG) in medium and platelet derived growth factor (PDGF) stimulated cells was evaluated by measuring 1) migration of cultured FLS monolayers (scratch assay); 2) proliferation using an MTT assay; and 3) protein expression by ELISA. For arthritis experiments, mice were injected with K/BxN sera on day 0. The glycolysis inhibitor bromopyruvate (BrPa; 5mg/kg) was injected daily i.p. beginning on day 0 after serum administration. Clinical arthritis scores were serially assessed. Joint histology was evaluated using a semiquantitative scoring system.

 

Results: One-dimensional 1H MRS spectra of aqueous extracts revealed 39.8±5.2% higher intracellular lactate accumulation in RA FLS compared with osteoarthritis (OA) FLS (p<0.01) indicating increased glycolytic rate. Of interest, FLS also displayed an unusual mitochondrial response, decreasing mitochondrial respiration (pmol O2/min) and increasing extracellular acidification (mpH/min) by 49.6±10.2% and 44±8.6% respectively after LPS stimulation. Glycolysis regulated key FLS functions that might contribute to cartilage damage in RA. For example, glycolysis inhibition with 2-DG (10 mM) reduced MMP3 and IL-6 secretion by 68±5.2% and 75±4.3%, respectively (p<0.01). Proliferation was reduced by 79±7.2% and migration by 63±15% (p<0.05). Finally, glycolysis inhibition by BrPa significantly decreased arthritis severity. Day 8 scores were 11.6±1.5 and 2±0.6 (P<0.01) for vehicle and BrPa-treated mice, respectively. Joint histology scores for vehicle and BrPa-treated mice for inflammation were 2.3±1.1 and 0.25±0.35 (p<0.01), bone erosion scores were 1.8±1.2 and 0.12±0.35 (p<0.01), and cartilage damage scores were 2.1±0.83 and 0.88±0.35 (p<0.01), respectively.

 

Conclusion: The metabolic profile in RA FLS suggests that glucose metabolism is abnormal and has shifted to ATP generation through oxidative phosphorylation to glycolysis. Blocking this pathway with a glycolysis inhibitor suppressed inflammatory arthritis in mice as well as the aggressive behavior of cultured RA FLS, including proliferation, cytokine secretion and cell migration. These data suggest that glycolysis inhibition may be disease modifying by directly modulating synoviocyte mediated functions and could be an effective strategy for arthritis.


Disclosure:

M. Guma,
None;

A. Lodi,
None;

A. Divakaruni,
None;

A. Murphy,
None;

S. Tiziani,
None;

G. S. Firestein,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeting-glycolysis-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.